Ellipticine
(Synonyms: 椭圆玫瑰树碱,NSC 71795) 目录号 : GC15305
Ellipticine (NSC 71795) 是一种有效的抗肿瘤剂；抑制 DNA 拓扑异构酶 II 的活性。
Cas No.:519-23-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | The cytotoxicity of ellipticine is determined by MTT test. Ellipticine (NSC 71795) is dissolved in DMSO (1 mM) and diluted in culture medium to final concentrations of 0, 0.1, 1, 5 or 10 μM. Cells in exponential growth are seeded at 1×104 per well in a 96-well microplate. After incubation the MTT solution is added, the microplates are incubated for 4 hours and cells lysed in 50% N,N-dimethylformamide containing 20% of sodium dodecyl sulfate (SDS), pH 4.5. The absorbance at 570 nm is measured. The mean absorbance of medium controls is subtracted as a background. The viability of control cells is taken as 100% and the values of treated cells are calculated as a percentage of control. The IC50 values are calculated using linear regression of the dose-log response curves[2]. |
References: [1]. Stiborova M, et al. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):13-23. | |
IC50 = 0.99 μM for L1210 lymphocytic leukemia cells [1]
Plant alkaloid ellipticine shows antitumor, mutagenic and cytotoxic activities by inhibition of DNA topoisomerase II activity. DNA topoisomerase II regulates the overwinding or underwinding of DNA by cuting DNA double helix, passing another unbroken DNA helix through it, and then reannealing the cut strands.
In vitro: Treatment mammalian DNA topoisomerase II reaction mixture with ellipticine resulted in the stimulation of DNA cleavage. The drug-stimulation of DNA cleavage is related to the formation of a ternary complex between topoisomerase II, DNA, and ellipticine. Ellipticine dose not inhibit enzyme-mediated DNA religation, however, it stimulates DNA breakage by enhancing the forward rate of cleavage [2]. Ellipticine showed growth inhibition activity on L1210 lymphocytic leukemia cells with a IC50 of 0.99 μM [1].
In vivo: Ellipticine was evaluated in P. berghei infected mice in the 4-day suppressive test. Ellipticine had a 100% inhibition versus controls on days 5 and 7 at an oral dose of 50 mg/kg/day, and the mean survival time (MST) was more than 40 days [3].
Clinical trial: Several ellipticine derivatives have been validated in clinical trials, however, due to adverse side-effects, no progress has be reported.
References:
[1] Paoletti C, Cros S, Xuong ND, Lecointe P, Moisand A. Comparative cytotoxic and antitumoral effects of ellipticine derivatives on mouse L 1210 leukemia. Chem Biol Interact. 1979 Apr;25(1):45-58.
[2] Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem. 1984 Jul 25;259(14):9182-7.
[3] Rocha e Silva LF, Montoia A, Amorim RC, Melo MR, Henrique MC, Nunomura SM, Costa MR, Andrade Neto VF, Costa DS, Dantas G, Lavrado J, Moreira R, Paulo A, Pinto AC, Tadei WP, Zacardi RS, Eberlin MN, Pohlit AM. Comparative in vitro and in vivo antimalarial activity of the indole alkaloids ellipticine, olivacine, cryptolepine and a synthetic cryptolepine analog. Phytomedicine. 2012 Dec 15;20(1):71-6.
| Cas No. | 519-23-3 | SDF | |
| 别名 | 椭圆玫瑰树碱,NSC 71795 | ||
| 化学名 | 5,11-dimethyl-6H-pyrido[4,3-b]carbazole | ||
| Canonical SMILES | CC1=C2C(NC3=CC=CC=C23)=C(C)C4=CC=NC=C14 | ||
| 分子式 | C17H14N2 | 分子量 | 246.31 |
| 溶解度 | ≥ 24.6mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.0599 mL | 20.2996 mL | 40.5992 mL |
| 5 mM | 0.812 mL | 4.0599 mL | 8.1198 mL |
| 10 mM | 0.406 mL | 2.03 mL | 4.0599 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。